Xiao Hui Ji
Director/Board Member at LEGEND BIOTECH CORPORATION
Net worth: 543 400 $ as of 2024-03-30
Profile
Xiao Hui Ji is the Chairman & Chief Executive Officer of Elpiscience Biopharma Ltd., a company he founded in 2017.
He is also currently serving as an Independent Director at Legend Biotech Corp.
since 2020.
Previously, Dr. Ji held the position of Chief Executive Officer at PharmaLegacy Laboratories (Shanghai) Co., Ltd.
He was also a Director at The BayHelix Group from 2008 to 2013 and Vice President-Business Development at Roche Holding AG from 2013 to 2016.
From 2017 to 2020, he worked as a Partner at LAV Management Co., Ltd.
In terms of education, Dr. Ji holds an MBA from The University of Chicago and has completed graduate studies at The University of Sheffield and China Medical University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
LEGEND BIOTECH CORP.
0.01% | 2022-12-30 | 19,376 ( 0.01% ) | 543 400 $ | 2024-03-30 |
Xiao Hui Ji active positions
Companies | Position | Start |
---|---|---|
LEGEND BIOTECH CORPORATION | Director/Board Member | 2020-04-30 |
Elpiscience Biopharma Ltd.
Elpiscience Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China. | Chief Executive Officer | 2016-12-31 |
Former positions of Xiao Hui Ji
Companies | Position | End |
---|---|---|
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV Management Co., Ltd. (LAV) is a venture capital subsidiary of Eli Lilly & Co. founded in 2008. The firm is headquartered in Shanghai, China with branches located in Central, Hong Kong and California, United States. | Corporate Officer/Principal | 2020-04-30 |
ROCHE HOLDING AG | Corporate Officer/Principal | 2016-11-30 |
The BayHelix Group | Director/Board Member | 2012-12-31 |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Chief Executive Officer | 2011-12-31 |
Training of Xiao Hui Ji
The University of Chicago | Masters Business Admin |
The University of Sheffield | Graduate Degree |
China Medical University | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 2 |
---|---|
ROCHE HOLDING AG | Health Technology |
LEGEND BIOTECH CORPORATION | Health Technology |
Private companies | 4 |
---|---|
LAV Management Co., Ltd.
LAV Management Co., Ltd. Investment ManagersFinance LAV Management Co., Ltd. (LAV) is a venture capital subsidiary of Eli Lilly & Co. founded in 2008. The firm is headquartered in Shanghai, China with branches located in Central, Hong Kong and California, United States. | Finance |
The BayHelix Group | |
Elpiscience Biopharma Ltd.
Elpiscience Biopharma Ltd. Pharmaceuticals: MajorHealth Technology Elpiscience Biopharma Ltd. engages in the development of cutting-edge immunotherapies to fight cancer. Its business scope includes technology research and development, transfer of own technology achievements and provision of related technical advice and technical services of biomedicine and biotechnology; import and export, and wholesale of mechanical equipment, electronic products, instrumentation, and plastic products. The company was founded on September 30, 2017 and is headquartered in Shanghai, China. | Health Technology |
PharmaLegacy Laboratories (Shanghai) Co., Ltd.
PharmaLegacy Laboratories (Shanghai) Co., Ltd. Miscellaneous Commercial ServicesCommercial Services PharmaLegacy Laboratories (Shanghai) Co., Ltd. engages in the provision of pharmacodynamics, pharmacokinetics, non-GLP toxicology, in vitro immunology, and three types of medical device evaluation services in line with international standards. It provides drug research & development preclinical research services such as pharmacodynamic research evaluation and pharmacokinetic research evaluation; device research & development preclinical research services such as preclinical effectiveness and safety evaluation of innovative medical devices; and experimental mice. The company was founded on March 7, 2008 and is headquartered in Shanghai, China. | Commercial Services |
- Stock Market
- Insiders
- Xiao Hui Ji